表皮生长因子受体酪氨酸激酶抑制剂在晚期非小细胞肺癌治疗中的作用。
The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer.
机构信息
Department of Hematology-Oncology, National University Cancer Institute, National University Health System, Singapore;
出版信息
J Thorac Dis. 2010 Sep;2(3):144-53. doi: 10.3978/j.issn.2072-1439.2010.02.03.6.
Abstract
The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) like erlotinib and gefitinib have been extensively studied. Multiple randomized trials have evaluated the role of EGFR TKIs in advanced stage non-small cell lung cancer (NSCLC) as a monotherapy in the first line, or subsequent lines of therapy, and in the first line in the maintenance setting or in combination with chemotherapy. Most of these trials showed positive results in particular for selected patients with specific clinical characteristic and somatic activating mutation of EGFR. A further understanding of the mechanism of primary and secondary resistance has led to the development of promising novel agents designed to overcome resistance to EGFR.
摘要
表皮生长因子受体酪氨酸激酶抑制剂（EGFR TKIs），如厄洛替尼和吉非替尼，已得到广泛研究。多项随机试验评估了 EGFR TKI 在晚期非小细胞肺癌（NSCLC）中的作用，包括一线单药治疗、二线及以上治疗、一线维持治疗或与化疗联合治疗，其中多数试验对特定临床特征和 EGFR 体细胞激活突变的特定患者显示出阳性结果。对原发性和获得性耐药机制的进一步了解，导致了有前途的新型药物的开发，旨在克服 EGFR 耐药性。
相似文献
1
The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer.表皮生长因子受体酪氨酸激酶抑制剂在晚期非小细胞肺癌治疗中的作用。
J Thorac Dis. 2010 Sep;2(3):144-53. doi: 10.3978/j.issn.2072-1439.2010.02.03.6.
2
Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.表皮生长因子受体突变（EGFR）检测对晚期非小细胞肺癌患者使用表皮生长因子受体靶向酪氨酸激酶抑制剂（TKI）药物疗效的预测：一项循证分析
Ont Health Technol Assess Ser. 2010;10(24):1-48. Epub 2010 Dec 1.
3
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.晚期表皮生长因子受体（EGFR）突变阳性非鳞状非小细胞肺癌的一线治疗
Cochrane Database Syst Rev. 2016 May 25(5):CD010383. doi: 10.1002/14651858.CD010383.pub2.
4
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).优化表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）中酪氨酸激酶抑制剂（TKI）的治疗顺序。
Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.
5
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
6
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.表皮生长因子受体酪氨酸激酶抑制剂作为非小细胞肺癌的初始治疗：重点关注表皮生长因子受体突变检测和突变阳性患者。
Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12.
7
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.非小细胞肺癌中表皮生长因子受体通路依赖性获得性表皮生长因子受体酪氨酸激酶抑制剂耐药。
Clin Lung Cancer. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039.
8
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.厄洛替尼或吉非替尼治疗铂类预处理复发的非小细胞肺癌和卵巢癌：系统评价。
Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24.
9
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.表皮生长因子受体（EGFR）酪氨酸激酶抑制剂治疗EGFR突变阳性非小细胞肺癌的特征及总生存期：对1660例日本患者的回顾性分析
Jpn J Clin Oncol. 2016 May;46(5):462-7. doi: 10.1093/jjco/hyw014. Epub 2016 Mar 13.
10
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.针对非小细胞肺癌细胞中的表皮生长因子受体：RNA 干扰与酪氨酸激酶抑制剂或西妥昔单抗联合的效果。
BMC Med. 2012 Mar 21;10:28. doi: 10.1186/1741-7015-10-28.
引用本文的文献
1
VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer.电视辅助胸腔镜手术（VATS）肺叶切除术使非小细胞肺癌患者能够接受辅助多西他赛-卡铂化疗。
J Thorac Dis. 2013 Oct;5(5):578-84. doi: 10.3978/j.issn.2072-1439.2012.02.05.
2
The efficacy of the inhalation of an aerosolized Group A streptococcal preparation in the treatment of lung cancer.吸入 A 组链球菌制剂气雾剂治疗肺癌的疗效。
Chin J Cancer Res. 2012 Dec;24(4):346-52. doi: 10.3978/j.issn.1000-9604.2012.10.08.
3
A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada.个体化治疗方法：在加拿大使用 EGFR 酪氨酸激酶抑制剂治疗非小细胞肺癌。
Curr Oncol. 2012 Apr;19(2):78-90. doi: 10.3747/co.19.1018.
4
Is T790M mutation the key in development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)?T790M突变是表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）耐药发生的关键因素吗？
J Thorac Dis. 2011 Mar;3(1):1-3. doi: 10.3978/j.issn.2072-1439.2011.01.06.
本文引用的文献
1
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.凡德他尼联合培美曲塞二线治疗晚期非小细胞肺癌的随机、双盲 III 期临床试验
J Clin Oncol. 2011 Mar 10;29(8):1067-74. doi: 10.1200/JCO.2010.29.5717. Epub 2011 Jan 31.
2
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.吉非替尼或化疗用于治疗具有突变型 EGFR 的非小细胞肺癌。
N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.
3
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.凡德他尼联合多西他赛对比多西他赛二线治疗晚期非小细胞肺癌患者（ZODIAC）：一项双盲、随机、III 期临床试验。
Lancet Oncol. 2010 Jul;11(7):619-26. doi: 10.1016/S1470-2045(10)70132-7.
4
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.厄洛替尼作为晚期非小细胞肺癌的维持治疗：一项多中心、随机、安慰剂对照的 3 期研究。
Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20.
5
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.奈拉替尼，一种不可逆的泛 ErbB 受体酪氨酸激酶抑制剂：在晚期非小细胞肺癌患者中进行的 II 期试验结果。
J Clin Oncol. 2010 Jun 20;28(18):3076-83. doi: 10.1200/JCO.2009.27.9414. Epub 2010 May 17.
6
Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.吉非替尼对比多西他赛用于既往铂类化疗的非小细胞肺癌患者的随机 III 期临床试验。
Clin Cancer Res. 2010 Feb 15;16(4):1307-14. doi: 10.1158/1078-0432.CCR-09-1903. Epub 2010 Feb 9.
7
Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).随机 III 期临床试验：吉非替尼对比继续含铂双药化疗用于日本晚期非小细胞肺癌患者：来自 west Japan thoracic oncology group trial (WJTOG0203) 的结果。
J Clin Oncol. 2010 Feb 10;28(5):753-60. doi: 10.1200/JCO.2009.23.3445. Epub 2009 Dec 28.
8
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.吉非替尼对比顺铂联合多西他赛用于治疗表皮生长因子受体突变的非小细胞肺癌患者（WJTOG3405）：一项开放标签、随机对照 3 期临床试验。
Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18.
9
Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.非小细胞肺癌对表皮生长因子受体酪氨酸激酶抑制剂的耐药性
Clin Cancer Res. 2009 Dec 15;15(24):7502-7509. doi: 10.1158/1078-0432.CCR-09-0189.
10
The role of EGFR inhibition in the treatment of non-small cell lung cancer.表皮生长因子受体抑制在非小细胞肺癌治疗中的作用。
Oncologist. 2009 Nov;14(11):1116-30. doi: 10.1634/theoncologist.2009-0054. Epub 2009 Nov 5.
Zotero 插件